ValiRx has entered into an evaluation agreement with Hokkaido University Japan, to investigate a drug candidate for use in oncology. The preclinical evaluation will run over the next 12-months and brings the number of assets currently under evaluation by ValiRx to two, having entered into an agreement with a leading London-based university for its triple negative breast cancer drug (Sept-21). This new agreement reinforces the company's commitment to its new strategy (see initiation Nov-21) and d ....
